
    
      This study is a prospective, randomized, open-label study.

      The CHB subjects who are cirrhosis will be randomized to two groups.

      The subjects who go into group A will be treated by nucleotide analogue (NA) combination with
      peginterferon alfa-2a,180Î¼g/week for 48 weeks.

      The subjects who go into group B will be treated by nucleotide analogue (NA) only for 48
      weeks.
    
  